Publications & Patents

Recent Publications

Wang Z, Serban BA, Serban MA. Recombinant Silk Fibroin Crystalline Regions as Biomaterial Alternatives to the Full-Length Protein. ACS Biomater. Sci. Eng. 2020, doi: 10.1021/acsbiomaterials.0c01103

Serban BA, Barrett-Catton E, Serban MA. Tetraethyl Orthosilicate-Based Hydrogels for Drug Delivery—Effects of Their Nanoparticulate Structure on Release Properties. Gels. 2020; 6(4):38, doi: 10.3390/gels6040038

Serban BA, Shi K, Alverson JB, Hoody J, Priestley ND, Park AH, Serban MA. A Single Application Cold-Chain Independent Drug Delivery System for Outer Ear Infections. ACS Biomater. Sci. Eng. 2020, 6(10), 5969-5978, doi: 10.1021/acsbiomaterials.0c01223

Serban MA, Skardal A. Hyaluronan chemistries for three-dimensional matrix applications. Matrix Biol. 2019, May;78-79:337-345. doi: 10.1016/j.matbio.2018.02.010. Epub 2018 Feb 10. PMID: 29438729.

Johnston ER, Miyagi Y, Chuah JA, Numata K, Serban MA. Interplay between Silk Fibroin’s Structure and Its Adhesive Properties. ACS Biomater. Sci. Eng. 2018, 4(8), 2815-2824, doi: 10.1021/acsbiomaterials.8b00544

Gels 20173(2), 19 - Featured article in Special issue 'Hydrogels for Drug Delivery', doi: 10.3390/gels3020019

Johnston ER, Smith TN, and Serban MA. Nanoparticulate Poly(glucaramide)-Based Hydrogels for Controlled Release ApplicationsGels 20173(2), 17; doi:10.3390/gels3020017 

Serban MA. Translational biomaterials-the journey from the bench to the market-think 'product'. Curr Opin Biotechnol. 2016, 40:31-34. doi: 10.1016/j.copbio.2016.02.009

Patents & Applications

Serban MA, Thixotropic Delivery Systems, PCT/US/20/039551

Serban MA, Skin Regeneration Device, SN 63/030,952

Serban MA. Thixotropic delivery systems for outer ear therapeutics. US patent application 62/891631. 2019 August.

Serban MA. The in vitro evaluation of an antibiotic controlled release system for the development of single-application otitis externa therapeutics. 2017. US 62/462,198 

Serban MA. Synergistic hyaluronan-based anti-inflammatory and anti-oxidant therapeutics,. 2017. US 62/571,011